LR-HEALTH-&-BEAUTY
18.6.2020 17:49:09 CEST | Business Wire | Press release
Today, the LR LIFETAKT NIGHT MASTER product was awarded the German Brand Award 2020. This is a sensational success for the LR Health & Beauty company, which launched a new segment in its health portfolio with this sleep drink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005674/en/
In the “Excellent Brands” competition, the vegan, holistically designed product impressed the jury in the “Health & Pharmaceuticals” category as one of the best product brands in the industry. The nightcap also received a “Special Mention” in the cross-industry category “Product Brand of the Year”, in which the jury awards a prize for special aspects of brand management. The German Brand Institute already distinguished LR as a winner in 2019 in the “Beauty & Care” category for its 5in1 Beauty Elixir product.
“The second award in a row for an advanced product development makes me and makes us all, incredibly proud and happy, and highlights our expertise in the health field,” says Andreas Friesch, CEO of LR Health & Beauty. “True to the company motto ‘More quality for your life’, we have developed a natural, effective, non-addictive product that is in touch with today’s trends*. Receiving recognition for this motivates us to keep developing innovative product solutions in the future,” Friesch says.
The secret of healthy sleep: LR LIFETAKT NIGHT MASTER
Healthy sleep improves quality of life, strengthens the immune system and heightens performance. Sleep is a desperate challenge for many but it does not have to be.*
The NIGHT MASTER sleep drink from LR LIFETAKT is an effective dietary supplement that ensures a restful sleep over the long term, in a healthy way that is non-addictive. Natural and scientifically proven active ingredients like hops and saffron extract, aloe vera, the amino acid L-tryptophan, magnesium and zinc, as well as a vitamin B complex distinguish the highly bioavailable formula. With its threefold effect, the product promotes relaxation when falling asleep and relaxation while sleeping through the night, as well as optimized regeneration. The product is vegan and it is gluten, lactose and sugar free. www.LRNightMaster.com
German Brand Award | German Design Council
The German Brand Award is a competition presented by the German Brand Institute. The Institute was founded by the German Design Council (Rat für Formgebung) in order to strengthen brand management as a crucial factor for success in companies in the national and international competitive field. It is a driving force of German brand economy, bringing together major brand-builders and stimulating brand dialog. The German Brand Award presented by the Institute is one of the most notable German brand awards.
The German Design Council is an independent and internationally active institution that supports companies in efficiently communicating design and brand competence, while at the same time aiming to strengthen design awareness among the general public. More information at: german-brand-award.com
LR Health & Beauty
Under the motto “More quality for your life”, the LR Group of Companies, with headquarters in the German city of Ahlen, markets diverse beauty and health products in 28 different countries. These include skin care and color cosmetics, dietary supplements and fragrances. LR Health & Beauty has made it its goal to improve the well-being and health of people through its product portfolio. That is why the company keeps developing new products – from the forces of nature combined with the latest scientific discoveries. Aloe Vera has been one of LR's key competences for over 18 years, where we only use the precious leaf fillet is used. With approximately 1,200 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe. The company has been assisting children in need and their families in various countries around the world through the LR Global Kids Fund e.V. – in a fast and non-bureaucratic way in cooperation with local established institutions.
*78% of Germans suffer from sleep problems, according to a nationwide CATI-representative survey conducted by Mente>factum on behalf of LR in 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom